At IBA we dare to develop innovative solutions pushing back the limits of science. We share ideas and know-how with our customers, our partners and leading experts to bring new solutions for the diagnosis and treatment of cancer and for the benefits of patients. We care of the well-being of patients and stakeholders as it is together that we complete our mission to Protect Enhance and Save lives.
Proton therapy is a form of radiotherapy considered by many specialists to be the most advanced and targeted cancer treatment. Because of its precision to target the tumor and its property to spare healthy tissues, proton therapy results in fewer side effects for the benefit of patients.
More than half of proton therapy facilities worldwide are IBA systems.
For both diagnosis and therapy, delivering exactly the prescribed dose to a precisely deﬁned area in the patient’s body is crucial.
IBA offers a full range of monitoring equipment and software enabling radiologists to perform the necessary checks and calibration procedures.
IBA RadioPharma Solutions offers solutions that combines equipment (cyclotron, synthesizer,...) and services for the establishment of radiopharmaceutical production centres in total compliance with current norms.
IBA Industrial focuses on two markets: the sterilization of single-use medical products and the improvement of the physical properties of polymers (crosslinking). IBA technology is faster and avoids all contamination by chemical products or radioactive.
Chief Strategy Officer, based in Louvain-la-Neuve, Belgium
Founder and Chief Research Officer, based in Louvain-la-Neuve, BelgiumAbout Yves
Chief Executive Officer, based in Louvain-la-Neuve, BelgiumAbout Olivier
President IBA Dosimetry, based in Schwarzenbruck, Germany
Chief Financial Officer, Based in Louvain-la-Neuve
Chief Human Resources Officer, based in Louvain-la-Neuve Belgium
Olivier Legrain, married and father of two children, graduated in economics from the Free University of Brussels (ULB) in 1992.
After four years as auditor with Didier Claes and Associates, he joined IBA SA in 1996 as Controller and was particularly involved in the IPO of the company. In 1998 he was appointed Chief Financial Officer (CFO) of Scanditronix Medical AB Sweden, the new subsidiary of IBA’s dosimetry activities.
He returned to the Belgian headquarters for a period of two years before taking the roles of Chairman and Chief Executive Officer (CEO) of Wellhöfer Scanditronix AB from 2001 to 2003. After having successfully lead the dosimetry branch of operations, Olivier Legrain took control of IBA Molecular in 2003 as President.
In 2011, he became responsible for establishing the future strategy of the IBA Group with his new role as Chief Strategy Officer (CSO), a strategy that he will apply himself as of May 2012 as CEO of the IBA Group.
Yves Jongen is Chief Research Officer for Ion Beam Applications. After founding IBA in 1986, he served as general manager and co-general manager of the company until March 2000, when he assumed his current role. Founded in Louvain-la-Neuve, Belgium, IBA has become a world leader in particle accelerator technology and its applications, particularly in medical imaging, cancer therapy and sterilization.
Prior to founding IBA, Mr. Jongen served for 16 years as manager of the UCL Cyclotron Research Center, a multidisciplinary organization established by the Catholic University of Louvain-la-Neuve (UCL), with several cyclotrons for fundamental and applied research. He holds a dozen patents and is the author of approximately 200 publications in the particle accelerator field and their applications.
Mr. Jongen graduated cum laude from UCL in 1970 as a Civil Engineer in electronics and earned an additional certificate in nuclear sciences. He has received the Georges Vanderlinden prize for science, given by the Belgium Royal Academy, for his work in Physics and Electricity, and shared the magazine Trends-Tendances 1997 Entrepreneur of the year honors for the French speaking part of Belgium with IBA CEO Pierre Mottet.
Founded by Yves Jongen in 1986, IBA is as a spin-off of the Cyclotron Research Center of the Catholic University of Louvain-la-Neuve (UCL), Belgium. Initially active in medical imaging, the company turned its attention to radiotherapy and developed cyclotrons and integrated proton therapy centers which are able to treat numerous forms of cancer with a degree of precision and efficacy never reached before.
In 1992, IBA expands activities into the industrial sector of sterilization and ionization by introducing the Rhodotron®, a new type of particle accelerator producing an electron beam based on a patented concept of the French Atomic Energy Commission.
IBA employees got together in 1997 in an employee buyout of the shares of the company. The purpose was to raise their involvement in, and reward their commitment to, the success of the company while also giving themselves the opportunity to drive its future.
In 1998 IBA introduces a cyclotron revolutionizing the world of proton therapy. The IBA isochronous cyclotron-based solution is today the simplest and most effective way to produce 230 MeV protons and will be used in more than 20 Proton therapy centers all over the world.
In June 1998, funds are raised on the Brussels stock market from an initial public offering to enable IBA to accelerate development through internal growth and acquisitions.
IBA enters the field of dosimetry through the acquisition of Scanditronix and Wellhöfer. The new entity called IBA Dosimetry represents the most important player worldwide in the dosimetry market and reinforces IBA's presence in the medical world.
IBA consolidates its strength in irradiation technologies with the acquisition of Radiation Dynamics, Inc. in February 1999. RDI was well established in the field of high-power low-energy E-beam accelerators used for heat shrinking and polymer modification applications.
Acquisition of Eastern Isotopes. In 2001, IBA becomes the majority shareholder of Eastern Isotopes, Inc., founded in 1993 in Sterling, Virginia, USA. Eastern Isotopes produces standard nuclear medicine products, while expanding into new PET imaging products, most notably FDG. The acquisition allows IBA to leverage its global expertise and innovation, and to offer its customers an international distribution network, more research isotopes and greater access to advanced cyclotron technology.
In 2001, the first patient is treated with a PT system installed by IBA at the Massachusetts General Hospital in Boston (now known as the Francis H. Burr Proton Therapy Center). Since then, through relentless effort and commitment, IBA has installed over half of the clinically driven PT centers worldwide and has become the undisputed leader in the field.
In 2004, the Indiana University Health Proton Therapy Center in Bloomington, Indiana (USA) treats its first patient using protons. A few months later, the Wanjie Proton Therapy Center in Zibo, China, starts treating patients with protons.
On April 20th 2006, IBA reveals its new corporate identity expressing its focus on the fight against cancer and its mission to Protect, Enhance and Save Lives. The different companies acquired throughout the years and IBA core activities are integrated in business units to form today’s worldwide group.
IBA activities for the production and distribution of radiopharmaceuticals are developed in Europe through the acquisition of the Schering radiopharmaceutical business and CIS bio International, making IBA the largest European PET radio-isotopes network. As a second step, in 2008, IBA fully acquires the CISBIO organization with a complete line of SPECT radiopharmaceuticals and additional FDG production facilities. The acquisition of CISBIO makes the company one of the world's largest players in the radiopharmaceutical business.
In June 2007, IBA opens a new facility in Beijing, China, giving the company Asian Headquarters to support all its business units in Asia. This move is part of an overall development program to optimize opportunities in one of the world’s fastest growing markets.
In 2008, the highly precise treatment mode “Pencil Beam Scanning”, developed in collaboration with Massachusetts General Hospital (MGH), is approved by the U.S. Food and Drug administration. A few months later, physicians at MGH’s Francis H. Burr Proton Therapy Center use Pencil Beam Scanning to treat patients.
Acquisition of CISBIO's drug discovery activities. For more than 25 years, CISBIO Bioassays, now a member of the IBA Group, has explored biology and immunoassay design to provide physicians, biologists, clinical chemists and scientists with enhanced solutions for improving patient care. CISBIO Bioassays dedicates its expertise to delivering cutting-edge assays and services to clinical medicine and pharmaceutical research.
In 2009, IBA’s proton therapy activity continues to grow with more successful developments in the field. The four beam modes of IBA’s Universal Nozzle, an all-in-one integrated system to treat patients, are utilized by physicians. Physicians at ProCure Treatment Center in Oklahoma City, Oklahoma (USA) use the new Inclined-beam Treatment Room and deploy the new Empath® 360°gantry room to treat patients.
IBA creates a strategic alliance with SK Capital Partners to create IBA Molecular Imaging, a jointly-owned company derived from IBA’s Molecular Imaging division. SK Capital Partners owns 60% of the company while IBA has a 40% stake.
Olivier Legrain becomes Chief Executive Officer replacing Pierre Mottet. Olivier Legrain joined the company in 1996 as Financial Controller. He further pursued his career in the company as President of the IBA Dosimetry business line from 1999 to 2003. From 2003 till 2010 he became President of the IBA Molecular business line. Thereafter he took over the role of Chief Strategy Officer of the Group.
Yves Jongen, Founder and Chief Research Officer of IBA, is nominated for the European Inventor of the Year Award from the European Patent Office for his lifetime contribution to developing new solutions in proton therapy and making this next generation targeted cancer treatment more accessible to cancer patients worldwide.
Following its strategy to focus on its proton therapy, accelerators and dosimetry activities, IBA sells Cisbio Bioassays, to Argos Soditic. Cisbio Bioassays develops and markets products and technologies used for in vitro diagnostics and drug discovery.
It is our Quality Policy to meet or exceed our defined customer’s expectations in all products and service provisions. This will be done by understanding and focusing on performance measures that are critical to our customer’s success. An important part of this is about meeting regulatory requirements.
Therefore, each of us in the IBA group is expected to be part of:
Our vision is to achieve sustainable business success through excellence in environment, health and safety!
Sustainable business advantage starts when we understand and address Environment, Health and Safety (EHS) issues, we have our own internal standards and systems to ensure that we comply with or exceed all guidelines, regulations and legal requirements.
IBA requires all Business Units and plants to: